Biolase Inc (NASDAQ: BIOL) closed the day trading at $0.17 down -6.88% from the previous closing price of $0.18. In other words, the price has decreased by -$0.0125 from its previous closing price. On the day, 1992601 shares were traded.
Ratios:
For a better understanding of BIOL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.68 and its Current Ratio is at 1.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, The Benchmark Company on June 19, 2019, initiated with a Speculative Buy rating and assigned the stock a target price of $2.
On April 25, 2017, Singular Research started tracking the stock assigning a Buy rating and target price of $2.50.
WallachBeth Downgraded its Buy to Hold on May 13, 2014, whereas the target price for the stock was revised from $4 to $2.50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIOL now has a Market Capitalization of 5.47M and an Enterprise Value of 16.81M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.11. Its current Enterprise Value per Revenue stands at 0.34 whereas that against EBITDA is -1.09.
Stock Price History:
Over the past 52 weeks, BIOL has reached a high of $47.10, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.2844, while the 200-Day Moving Average is calculated to be 2.5791.
Shares Statistics:
Over the past 3-months, BIOL traded about 5.47M shares per day on average, while over the past 10 days, BIOL traded about 17.4M shares per day. A total of 32.52M shares are outstanding, with a floating share count of 30.69M. Insiders hold about 5.64% of the company’s shares, while institutions hold 4.58% stake in the company. Shares short for BIOL as of Mar 15, 2024 were 288.87k with a Short Ratio of 0.05, compared to 678.61k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.89% and a Short% of Float of 0.89%.
Earnings Estimates
Current recommendations for the stock of the company come from 2 analysts. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.21, while EPS last year was -$18. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.24 and -$0.4 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.11, with 2 analysts recommending between -$0.09 and -$0.13.
Revenue Estimates
3 analysts predict $10M in revenue for the current quarter. It ranges from a high estimate of $10.49M to a low estimate of $9.7M. As of the current estimate, Biolase Inc’s year-ago sales were $10.47M, an estimated decrease of -4.50% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $14.09M, a decrease of -1.40% over than the figure of -$4.50% in the same quarter last year. There is a high estimate of $14.3M for the next quarter, whereas the lowest estimate is $13.79M.
A total of 3 analysts have provided revenue estimates for BIOL’s current fiscal year. The highest revenue estimate was $52M, while the lowest revenue estimate was $51M, resulting in an average revenue estimate of $51.5M. In the same quarter a year ago, actual revenue was $49.16M, up 4.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $55.5M in the next fiscal year. The high estimate is $57.21M and the low estimate is $53.6M. The average revenue growth estimate for next year is up 7.80% from the average revenue estimate for this year.
